HC Wainwright Forecasts Lower Earnings for Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Investment analysts at HC Wainwright reduced their FY2026 earnings estimates for Niagen Bioscience in a note issued to investors on Wednesday, August 5th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.14 per share for the year, down from their prior forecast of $0.28. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Niagen Bioscience’s current full-year earnings is $0.21 per share. HC Wainwright also issued estimates for Niagen Bioscience’s Q4 2026 earnings at $0.02 EPS and FY2027 earnings at $0.14 EPS.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. The company had revenue of $29.78 million during the quarter, compared to analyst estimates of $29.95 million. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%.

A number of other equities research analysts have also commented on NAGE. Wall Street Zen lowered Niagen Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Friday, July 17th. Freedom Capital raised Niagen Bioscience to a “strong-buy” rating in a research note on Monday, July 6th. Roth Capital restated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday. Finally, Canaccord Genuity Group lowered their target price on Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $10.33.

Niagen Bioscience Trading Up 2.7%

NASDAQ:NAGE opened at $3.04 on Friday. The stock has a market capitalization of $242.11 million, a P/E ratio of 16.89 and a beta of 2.09. Niagen Bioscience has a 1 year low of $2.87 and a 1 year high of $11.29. The firm has a 50 day moving average of $3.40 and a 200-day moving average of $4.32.

Institutional Investors Weigh In On Niagen Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. bought a new position in Niagen Bioscience in the third quarter valued at about $37,522,000. SteelPeak Wealth LLC bought a new stake in Niagen Bioscience during the 1st quarter worth about $14,875,000. Arrowstreet Capital Limited Partnership bought a new stake in Niagen Bioscience during the 3rd quarter worth about $13,405,000. UBS Group AG acquired a new position in Niagen Bioscience during the 3rd quarter valued at about $11,160,000. Finally, Qube Research & Technologies Ltd acquired a new position in Niagen Bioscience during the 3rd quarter valued at about $8,175,000. 15.41% of the stock is owned by institutional investors and hedge funds.

Niagen Bioscience News Roundup

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Expanded Walmart distribution: Niagen launched its Tru Niagen healthy-aging supplement on Walmart.com, increasing access through a major e-commerce platform and diversifying its online sales channels. The move could support consumer reach, revenue growth and brand visibility. Niagen Bioscience Launches Tru Niagen on Walmart.com
• Positive Sentiment: Potentially higher fair value: Coverage discussing a new aging study argues that Niagen’s NAD+ and healthy-aging opportunity may justify a higher valuation, offering a bullish long-term view of the company’s research and commercial prospects. Niagen Bioscience On New Aging Study And the Case for a Higher Fair Value
• Neutral Sentiment: Buy rating retained: Despite lowering its estimates, HC Wainwright maintained a “Buy” rating on NAGE, indicating the analyst still sees longer-term upside.
• Negative Sentiment: Sharp earnings-estimate reductions: HC Wainwright cut its Q3 2026 EPS forecast to $0.02 from $0.08 and reduced its Q4 2026 forecast to $0.02 from $0.10. It also lowered its FY2026 estimate to $0.14 from $0.28.
• Negative Sentiment: Weaker 2027 outlook: The firm reduced FY2027 EPS expectations to $0.14 from $0.36, while cutting quarterly 2027 forecasts, including Q1 to $0.03 from $0.06, Q2 to $0.03 from $0.08, Q3 to $0.04 from $0.10 and Q4 to $0.05 from $0.12. These revisions suggest more cautious assumptions about near-term profitability and could weigh on valuation.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.